Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies

摘要

Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.

主权项

1. A method comprising a step of:
administering therapy to a human subject having prostate cancer and expressing an androgen receptor variant that lacks the ligand binding domain, wherein the androgen receptor variant that lacks the ligand binding domain is AR-V7, which therapy comprises administering a compound of formula I:or a pharmaceutically acceptable salt thereof, wherein R1 is H and R2 is benzimidazole.